Edgewise Therapeutics

EWTX · NASDAQ

$39.75+$1.83 (+4.83%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $37.92

EWTX analyst rating

BuyConsensus of 9 analysts over the last 12 months. 89% rate it a buy.

Strong buy0
Buy8
Hold1
Underperform0
Sell0

12-month price target · 15 analysts

Average $53.04 (+33.4% upside)

Low: $36.36
Now: $39.75
High: $69.30

Upgrades and downgrades

The latest rating actions, newest first

EWTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
William Blair	Oct 16, 2026	Initiates	Outperform	—	52%
HC Wainwright & Co.	Sep 21, 2026	Maintains	Buy	$45.00 → $57.00	29%
JP Morgan	Aug 20, 2026	Maintains	Overweight	$53.00 → $60.00	44%
Goldman Sachs	Aug 11, 2026	Maintains	Neutral	$32.00 → $36.00	51%
Evercore ISI Group	Jul 20, 2026	Maintains	Outperform	$45.00 → $55.00	51%
Oppenheimer	Jul 9, 2026	Initiates	Outperform	$51.00	17%
Guggenheim	Jul 6, 2026	Maintains	Buy	$41.00 → $51.00	45%
RBC Capital	Jun 17, 2026	Maintains	Outperform	$48.00 → $59.00	49%
Goldman Sachs	Jun 17, 2026	Maintains	Neutral	$20.00 → $32.00	51%
HC Wainwright & Co.	Jun 16, 2026	Maintains	Buy	$45.00	29%

The case for and against

Updated Oct 15, 2026

Bull case

Edgewise Therapeutics is viewed positively because EDG-7500 has shown broad Phase 2 efficacy in both oHCM and nHCM, including roughly 55% resting LVOT-G reduction, about 65% NT-proBNP reduction in nHCM, and meaningful gains in KCCQ and NYHA class, while preserving LVEF and avoiding heart-failure events across 53 patients. The case is further strengthened by differentiation potential versus cardiac myosin inhibitors through simpler monitoring, possible REMS-free use, and a favorable safety profile across 240+ patients and 700+ echocardiograms. Financially, the Servier transaction delivered $1.55 billion upfront and up to $2.65 billion total consideration, leaving approximately $2.05 billion pro forma cash and zero debt, which should fund Phase 3 development and reduce dilution risk.

Bear case

Edgewise Therapeutics is a high-risk, precommercial biotech whose investment case depends almost entirely on EDG-7500, yet the dataset remains small at 53 patients over 12 weeks and does not yet prove that Phase 3 will replicate the reported LVOT-gradient, NT-proBNP, and KCCQ benefits. The negative outlook is driven by the possibility that FDA requires a REMS or echo-monitoring cadence at EOP2, which would erase the hoped-for operational differentiation, while safety concerns around systolic dysfunction, atrial arrhythmias, and exposure-linked LVEF effects remain central class risks. Financially, the company has no commercial products and could face meaningful funding pressure if the Servier transaction stalls or if Phase 3 and manufacturing costs rise, with even the downside case implying the stock could trade near cash, about $10.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.